Avivagen Management

Management Kriterienprüfungen 3/4

Avivagen's CEO ist G. F. Anthony, ernannt in Feb 2017, hat eine Amtszeit von 7.25 Jahren. besitzt direkt 0.84% der Aktien des Unternehmens, im Wert von CA$3.28K. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 7.1 Jahre bzw. 14.8 Jahre.

Wichtige Informationen

G. F. Anthony

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	7.3yrs
Eigentum des Geschäftsführers	0.8%
Durchschnittliche Amtszeit des Managements	7.2yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	14.8yrs

Jüngste Management Updates

Recent updates

It's Unlikely That Avivagen Inc.'s (CVE:VIV) CEO Will See A Huge Pay Rise This Year

Apr 02

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von G. F. Anthony im Vergleich zu den Einnahmen von Avivagen verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jul 31 2023	n/a	n/a	-CA$5m
Apr 30 2023	n/a	n/a	-CA$6m
Jan 31 2023	n/a	n/a	-CA$6m
Oct 31 2022	CA$400k	CA$361k	-CA$6m
Jul 31 2022	n/a	n/a	-CA$6m
Apr 30 2022	n/a	n/a	-CA$6m
Jan 31 2022	n/a	n/a	-CA$7m
Oct 31 2021	CA$539k	CA$469k	-CA$6m
Jul 31 2021	n/a	n/a	-CA$6m
Apr 30 2021	n/a	n/a	-CA$5m
Jan 31 2021	n/a	n/a	-CA$5m
Oct 31 2020	CA$420k	CA$362k	-CA$5m
Jul 31 2020	n/a	n/a	-CA$5m
Apr 30 2020	n/a	n/a	-CA$5m
Jan 31 2020	n/a	n/a	-CA$5m
Oct 31 2019	CA$412k	CA$362k	-CA$5m
Jul 31 2019	n/a	n/a	-CA$5m
Apr 30 2019	n/a	n/a	-CA$5m
Jan 31 2019	n/a	n/a	-CA$5m
Oct 31 2018	CA$431k	CA$363k	-CA$5m
Jul 31 2018	n/a	n/a	-CA$5m
Apr 30 2018	n/a	n/a	-CA$5m
Jan 31 2018	n/a	n/a	-CA$5m
Oct 31 2017	CA$447k	CA$266k	-CA$5m

Vergütung im Vergleich zum Markt: Unzureichende Daten, um festzustellen, ob die Gesamtvergütung von G. F. im Vergleich zu Unternehmen ähnlicher Größe auf dem Markt Canadian angemessen ist.

Entschädigung vs. Einkommen: G. F.Die Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

G. F. Anthony (68 yo)

7.3yrs

Amtszeit

CA$399,892

Vergütung

Mr. G. F. Kym Anthony has been Chief Executive Officer of Avivagen Inc. since May 2019 serves as its Director since April 4, 2014 and serves as its Vice Chairman since April 19, 2023. Mr. Anthony served as...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
G. F. Anthony	CEO & Vice Chairman	7.3yrs	CA$399.89k	0.84% CA$ 3.3k
Graham Burton	Co-Founder	7.2yrs	CA$134.37k	0.47% CA$ 1.8k
Ira Levy	Interim Chief Financial Officer	1.8yrs	CA$120.38k	keine Daten
James Nickerson	President and Executive VP of Business Development & Product Innovation	2.4yrs	keine Daten	keine Daten
Drew Basek	Director of Investor Relations	7.3yrs	keine Daten	keine Daten
Tracy Gillett	Director of Companion Animal & Marketing Manager	no data	keine Daten	keine Daten

7.2yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: Das Managementteam von VIV ist erfahren und erfahren (durchschnittliche Amtszeit: 7.1 Jahre).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
G. F. Anthony	CEO & Vice Chairman	10.2yrs	CA$399.89k	0.84% CA$ 3.3k
Graham Burton	Co-Founder	18.8yrs	CA$134.37k	0.47% CA$ 1.8k
Murray McLaughlin	Member of Business & Technology Advisory Team	14.8yrs	keine Daten	keine Daten
Christopher Newman	Member of Scientific Advisory Board	17.3yrs	keine Daten	keine Daten
David Hankinson	Independent Chairman of the Board	18.8yrs	CA$71.17k	0.029% CA$ 113.3
Richard Smith	Member of Business and Technology Advisory Team	14.8yrs	keine Daten	keine Daten
Paul Mesburis	Independent Lead Director	8.2yrs	CA$97.13k	0.028% CA$ 110.2
Jolyon Burton	Member of Business and Technology Advisory Team	14.8yrs	keine Daten	keine Daten
Joseph Dunn	Member of Business and Technology Advisory Team	14.8yrs	keine Daten	keine Daten
John Oliver	Chairman of the Business and Technology Advisory Team	14.8yrs	keine Daten	keine Daten
John Brennan	Member of Business and Technology Advisory Team	14.8yrs	keine Daten	keine Daten

14.8yrs

Durchschnittliche Betriebszugehörigkeit

54yo

Durchschnittliches Alter

Erfahrener Vorstand: VIVDie Vorstandsmitglieder sind sehr erfahren ( 14.8 ).

Avivagen Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Avivagen Inc., Annual General Meeting, Apr 19, 2023

Insufficient new directors

Avivagen Inc. Appoints Ira Levy as Interim CFO

Insufficient new directors

Avivagen Inc., Annual General Meeting, Apr 08, 2022

Avivagen Inc., Annual General Meeting, Apr 08, 2022

Recent updates

Third quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.03 loss in 3Q 2022)

Second quarter 2023 earnings released: CA$0.016 loss per share (vs CA$0.022 loss in 2Q 2022)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Avivagen Inc., Annual General Meeting, Apr 19, 2023

Insufficient new directors

Avivagen Inc. announced that it expects to receive CAD 1 million in funding

Avivagen Inc. Appoints Ira Levy as Interim CFO

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Avivagen Announces Successful Completion of Formal Safety and Toxicology Evaluation of Fully Oxidized Beta-Carotene (OxBC)

Avivagen Inc. Announces Oxidized Carotenoid-Based Feed Additive Product Receive Approval for Use in China

Insufficient new directors

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Avivagen Inc. announced that it has received CAD 5.678 million in funding

Avivagen Announces Approval in Vietnam

Avivagen Inc., Annual General Meeting, Apr 08, 2022

Avivagen Inc., Annual General Meeting, Apr 08, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

No longer forecast to breakeven

Third quarter 2021 earnings released: CA$0.026 loss per share (vs CA$0.019 loss in 3Q 2020)

No longer forecast to breakeven

Second quarter 2021 earnings released: CA$0.041 loss per share (vs CA$0.034 loss in 2Q 2020)

Forecast to breakeven in 2023

It's Unlikely That Avivagen Inc.'s (CVE:VIV) CEO Will See A Huge Pay Rise This Year

Avivagen Inc. Announces Manuscript Reporting the Benefits of OxC-betaTM Livestock for Broiler Poultry Has Been Approved for Publication by Poultry Science

First quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.037 loss in 1Q 2020)

Revenue behind estimates

Avivagen Inc. Announces the Publication of Its New Zealand OxC-beta Livestock Dairy Trial for Use Against Sub-Clinical Mastitis

Avivagen Inc. has completed a Composite Units Offering in the amount of CAD 7.5 million.

New 90-day high: CA$0.67

Mimi's Rock Corp. and Avivagen Announce Launch of Dr. Tobias Beta Blend on Amazon.Com

Avivagen Inc., Annual General Meeting, Apr 08, 2021

Avivagen Inc. Announces Six Tonne Order of OxC-beta Livestock from New Customer in Mexico

New 90-day high: CA$0.66

Analysts update estimates

Revenue behind estimates

Full year 2020 earnings released: CA$0.12 loss per share

New 90-day high: CA$0.59

New 90-day high: CA$0.55

New 90-day low: CA$0.40

Avivagen Announces Record Four Tonne Order from UNAHCO

Avivagen Inc. Receives Multiple New Orders and Joins Influential Industry Associations in Mexico

Avivagen Inc. Receives 10 Tonne Purchase Order for OxC-Beta Livestock from Large North American Client

New 90-day high: CA$0.51

Analysts update estimates

Third quarter earnings released

New 90-day low - CA$0.41

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter